ArticlePatient education and counseling2021
PGx in psychiatry: Patients' knowledge, interest, and uncertainty management preferences in the context of pharmacogenomic testing.
Article in Patient education and counseling, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Genetic testing in psychiatry, the perceptions of healthcare workers and patients: a mini review.Frontiers in public health · 2024Pooled it
- A randomized trial to evaluate attitudes regarding pharmacogenomics among pregnant and pediatric populations: design and baseline characteristics.The pharmacogenomics journal · 2026Trial
- Perceptions of Pharmacogenomic Testing Among People With Treatment Resistant Depression: Legitimization as a Facilitator of Acceptance.Journal of genetic counseling · 2026Article
- The clinical value of pharmacogenomics in the pharmacotherapy of common psychiatric disorders: a macroscopic analysis based on real-world data.BMC psychiatry · 2026Article
- Pharmacogenetic Testing of Children and Adolescents with Mental Health Conditions: Real-World Experiences.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Assessing the Impact of Simplified Language on a Patient-Facing Pharmacogenetic Report: A User Comprehension Study.Journal of personalized medicine · 2025Article
- Factors influencing patient decision-making on a multimodal precision medicine algorithm for depression: a qualitative European multicentre study of the PROMPT consortium.Frontiers in psychiatry · 2025Article
- Assessing the views and opinions of psychiatric patients receiving genome-guided treatment within the scope of the PREPARE preemptive pharmacogenomics clinical study.Frontiers in pharmacology · 2025Article
- Normalising the Implementation of Pharmacogenomic (PGx) Testing in Adult Mental Health Settings: A Theory-Based Systematic Review.Journal of personalized medicine · 2024Review
- Exploring psychological variables in users' health information-seeking behavior: A systematic review.Journal of education and health promotion · 2024Review
- Exploring perceived barriers and attitudes in young adults towards antidepressant pharmacotherapy, including the implementation of pharmacogenetic testing to optimize prescription practices.Frontiers in pharmacology · 2024Article
- A survey in Austria supports the significance of genetic counseling and pharmacogenetic testing for mental illness.Frontiers in psychiatry · 2024Article
- Understanding parents uncertainty sources and management strategies while caring for a child diagnosed with a hematologic cancer.PEC innovation · 2023Article
- A randomized controlled trial of analogue pharmacogenomic testing feedback for psychotropic medications.PEC innovation · 2023Article
- Development and Validation of the Minnesota Assessment of Pharmacogenomic Literacy (MAPL).Journal of personalized medicine · 2022Article
- Exploring perceptions, knowledge, and attitudes regarding pharmacogenetic testing in the medically underserved.Frontiers in genetics · 2022Article
- What Are the Barriers and Enablers to the Implementation of Pharmacogenetic Testing in Mental Health Care Settings?Frontiers in genetics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
objectivePharmacogenomic testing (PGx) is expanding into psychiatric care. PGx could potentially offer a unique benefit to psychiatric patients, providing information about patients' reaction to medications that could reduce the time and financial burdens of drug optimization. The aims of this study were to: (1) examine psychiatry patients' familiarity and interest in PGx, and (2) explore how Uncertainty Management Theory relates to PGx testing in psychiatry.
methodWe surveyed psychiatric patients, measuring their PGx familiarity and interest, attitudes toward PGx testing, and preference for managing illness uncertainty.
resultsWe analyzed data from 598 patients. Patients' familiarity of PGx was low, but interest was high. Thirty percent of patients were familiar with the test from communication with their healthcare provider or their own online health information seeking. A preference for seeking information was a significant positive predictor of testing interest (p < .001).
conclusionPsychiatric patients were interested in PGx testing, regardless of their uncertainty management preferences. PRACTICE IMPLICATIONS: This study is one of the first to examine psychiatric patients' perspectives on PGx testing in mental health care. Our findings show that psychiatric patients are interested in the test and are familiar enough with PGx to be included in future research on the topic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.